Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO and TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX...
Kalytera Therapeutics ( OTCQB:KALTF ): FY GAAP EPS of $0.04 beats by $0.05. More news on: Kalytera Therapeutics, Inc., Earnings news and commentary, Energy stocks news, , Read more ...
SAN FRANCISCO and TEL AVIV, Israel, May 01, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today reported financial results for the year ended December 31 2018. (All dollars U.S. unless otherwise noted.) Investor...
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANSISCO and TEL AVIV, Israel, April 26, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (T...
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ SAN FRANCISCO and TEL AVIV, Israel, April 17, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY) (OTCQB:KALTF) announced today that it...
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ SAN FRANCISCO and TEL AVIV, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY and OTCQB: KALTF) announced that it ha...
Kalytera Therapeutics ( OTCQB:KALTF ) reports positive data from its ongoing Phase 2 study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. More news on: Kalytera Therapeu...
SAN FRANCISCO and TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced positive data from its ongoing Phase 2 clinical study evaluating cannabidiol (“ CBD ”...
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ SAN FRANCISCO and TEL AVIV, Israel, March 07, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the " Company " or " Kalytera ") is pleased to announce the closing of...
SAN FRANCISCO and TEL AVIV, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has initiated a food effect study (“ Study KAL-07”) , as part of its lead product d...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...